Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C, Buonsanti C, Miotto D, Mapp C, Villa A, Arrigoni G, Fabbri L M, Sinigaglia F
Roche Milano Ricerche, Milano, Italy.
J Clin Invest. 2001 Jun;107(11):1357-64. doi: 10.1172/JCI12655.
In vitro polarized human Th2 cells preferentially express the chemokine receptors CCR3, CCR4, and CCR8 and migrate to their ligands: eotaxin, monocyte-derived chemokine (MDC), thymus- and activation-regulated chemokine (TARC), and I-309. We have studied the expression of chemokines and chemokine receptors in the airway mucosa of atopic asthmatics. Immunofluorescent analysis of endobronchial biopsies from six asthmatics, taken 24 hours after allergen challenge, demonstrates that virtually all T cells express IL-4 and CCR4. CCR8 is coexpressed with CCR4 on 28% of the T cells, while CCR3 is expressed on eosinophils but not on T cells. Expression of the CCR4-specific ligands MDC and TARC is strongly upregulated on airway epithelial cells upon allergen challenge, suggesting an involvement of this receptor/ligand axis in the regulation of lymphocyte recruitment into the asthmatic bronchi. In contrast to asthma, T cells infiltrating the airways of patients with chronic obstructive pulmonary disease and pulmonary sarcoidosis produce IFN-gamma and express high levels of CXCR3, while lacking CCR4 and CCR8 expression. These data support the role of CCR4, of its ligands MDC and TARC, and of CCR8 in the pathogenesis of allergen-induced late asthmatic responses and suggest that these molecules could be considered as targets for therapeutic intervention.
体外极化的人Th2细胞优先表达趋化因子受体CCR3、CCR4和CCR8,并迁移至其配体:嗜酸性粒细胞趋化因子、单核细胞衍生趋化因子(MDC)、胸腺和活化调节趋化因子(TARC)以及I-309。我们研究了特应性哮喘患者气道黏膜中趋化因子和趋化因子受体的表达。对6名哮喘患者在变应原激发后24小时采集的支气管活检组织进行免疫荧光分析,结果显示几乎所有T细胞均表达IL-4和CCR4。CCR8与CCR4在28%的T细胞上共表达,而CCR3在嗜酸性粒细胞上表达,但在T细胞上不表达。变应原激发后,气道上皮细胞上CCR4特异性配体MDC和TARC的表达强烈上调,提示该受体/配体轴参与调节淋巴细胞向哮喘支气管的募集。与哮喘不同,浸润慢性阻塞性肺疾病和肺结节病患者气道的T细胞产生IFN-γ并高表达CXCR3,而缺乏CCR4和CCR8表达。这些数据支持CCR4及其配体MDC和TARC以及CCR8在变应原诱导的迟发性哮喘反应发病机制中的作用,并提示这些分子可被视为治疗干预的靶点。